on Mainz BioMed N.V.
Mainz Biomed Partners with EDX Medical on Diagnostic Tech
Mainz Biomed N.V., a company specializing in molecular genetics diagnostics, has announced a partnership with EDX Medical Group, based in the UK. The collaboration aims to expand EDX Medical's product portfolio in the UK by utilizing Mainz Biomed’s molecular diagnostic technology. This partnership is focused on enhancing early cancer detection.
Guido Baechler, CEO of Mainz Biomed, emphasized the partnership's aim to improve cancer diagnostics access in the UK. Dr. Mike Hudson, CEO of EDX Medical, highlighted their commitment to integrating molecular biomarkers for better cancer testing.
This partnership underlines both companies' dedication to advancing diagnostic technology, potentially improving patient outcomes through early disease detection. Mainz Biomed continues to develop its diagnostic solutions, including their flagship product, ColoAlert®, for early detection of colorectal cancer.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news